Pharmaceutical Market Europe • September 2022 • 42-44
APPOINTMENTS
Roche
Thomas Schinecker
Roche has appointed Thomas Schinecker as its new chief executive officer. He most recently served as chief of the diagnostics division at Roche, having been appointed as Roche Diagnostics’ CEO in 2019. During his 20-year career at Roche, Schinecker held various international roles of varying responsibility within the company, including as head of marketing and sales, general manager at regional offices. In August 2011, he served as the company’s chief executive officer and president of Roche Sequencing. Schinecker was also the head of marketing and sales for Roche Diagnostics in Austria. In 2003, he worked on the company’s global management programme in Basel. Since August 2019, Schinecker has served as a member of the Innovation Board of Labor, Berlin.
Vicebio
Emmanuel Hanon
Vicebio has appointed Emmanuel Hanon as its chief executive officer and will support the company in creating a vaccine to tackle respiratory syncytial virus (RSV). Prior to Vicebio, Hanon served at GSK for 20 years, most recently as its senior vice president, head of R&D for GSK Vaccine. A virologist and immunologist, Hanon has contributed to next-generation adjuvants in vaccines for malaria, pandemic influenza and shingles.
Eli Lilly
Eric Dozier
Eli Lilly has appointed Eric Dozier as its senior vice president, human resources and diversity. Dozier currently serves as vice president and chief commercial officer for Loxo@Lilly. During his almost 25-year career at the company, he has served as chief marketing officer for the Japan affiliate. Dozier served as vice president of global ethics and compliance. He also served as senior marketing director, global neuroscience brands.
Eli Lilly
Winselow Tucker
Eli Lilly has appointed Winselow Tucker as senior vice president and chief commercial officer for Loxo@Lilly. Winselow joins the company from Bristol Myers Squibb, where he served as senior vice president and general manger of US hematology, leading commercial operations, before becoming senior vice president. Prior to his work at Bristol Myers Squibb, he served in leadership roles at Novartis and Celgene.
Ixaka
Karen Miller
Ixaka has appointed Karen Miller as its chief scientific officer. Miller joins Ixaka with over 30 years’ experience in the biotech and pharma industry, having served as senior vice president, pipeline research, at Adaptimmune. Miller was also vice president, head of the Immunology Innovation Fund at GSK, where she sourced and assessed project opportunities across multiple therapeutic areas including oncology.
Charnwood Molecular
Lee Patterson
Charnwood Molecular has appointed Lee Patterson as its chief executive officer. With a background of 33 years in pharmaceutical research and development, Patterson held senior executive leadership roles at Quanticate, Concept Life Sciences and Covance and brings an extensive scientific background in pathological and biomedical sciences.
Centauri Therapeutics
Jennifer Schneider
Centauri Therapeutics has appointed Jennifer Schneider as its new chief executive officer.
Schneider joins with experience spanning 20 years working worldwide with life sciences companies, universities and non-governmental organisations. She recently served as executive officer for the Global Antibiotic Research & Development Partnership (GARDP), North America.
Elevar Therapeutics
Jan Van Tornout
Elevar Therapeutics has appointed Jan Van Tornout as chief medical officer. He has over 25 years’ experience in the medical industry as a haematologist-oncologist, genetic epidemiologist and pharma-biotech executive. He was acting chief medical officer of Tyme Technologies. He also worked for Moleculin Biotech, Bright Peak Therapeutics, GSK, Bristol-Myers Squibb and Amgen.
Centauri Therapeutics
Helen Bright
Centauri Therapeutics has appointed Helen Bright as vice president of R&D. Bright recently served as head of infection biology at Medicines Discovery Catapult, where she supported the discovery and development of anti-infectives and vaccines. With over 30 years’ experience in infectious diseases, she has served in scientific and leadership roles at AstraZeneca, Pfizer and GSK.
Takeda UK and Ireland
Seyda Atadan Memis
Takeda UK and Ireland has appointed Seyda Atadan Memis as its new general manager. Jon Neal is changing roles within the company to become Takeda’s head of portfolio and pipeline for Europe and Canada. Memis has most recently served as the general manager of Takeda in Turkey over the last four years. In this role, she launched six innovative medicines and led Takeda to become one of the top ten companies within the market and she also oversaw the integration of Takeda and Shires. She is a trained chemical engineer and also holds an MBA. She brings a strong track record of success, with a career spanning over 20 years’ experience in the pharmaceutical industry across multiple commercial roles.
Amarin
Henrik Asmussen
Amarin has appointed Henrik Asmussen as general manager of mid-Europe and the Nordics. Asmussen brings over 20 years’ industry experience to the Amarin team, joining the company from Amgen, where he served as general manager of Switzerland. Prior to this, he held senior leadership roles with AstraZeneca, including as global Crestor director Europe and as global brand director cardiovascular EMEA.
Amarin
Salvador Lopez
Amarin has appointed Salvador Lopez as its general manager for Spain and Portugal. A lawyer with a Master’s in Business Law from the Universidad Antonio de Nebrija, he also holds an MBA from the IE business school in Madrid. Lopez brings over 20 years’ experience as a legal professional, having held senior legal counsel roles at Janssen. He also served at Mundipharma International as general manager, mid-Europe.
Vaccentis
Martin Munte
Vaccentis has appointed Martin Munte as chief executive officer. Munte has a wealth of leadership experience in general management, policy and regulatory matters. He previously served at Amgen for 12 years as general manager for Amgen Slovakia and as the external access engagement lead for Europe. Prior to Amgen, he also served as a marketing and sales director, specialty care, at AstraZeneca from 2007 to 2009.
Tiziana Life Sciences
Matthew Davis
Tiziana Life Sciences has appointed Matthew Davis as chief medical officer and acting chief scientific officer, effective immediately. Davis brings 25 years’ experience in the pharmaceutical industry to the role, having served as chief scientific officer and chief medical officer at Endo Pharmaceuticals. He also served as chief medical officer for Lupin and URL Pharma. Davis also served as director, oncology clinical development at Eisai.
AstraZeneca
Michel Demaré
AstraZeneca has appointed Michel Demaré as the chair-designate of the Board. Demaré succeeds Leif Johansson and his new role starts in 2023. Demaré was appointed to the Board of AstraZeneca in 2019 as an independent non-executive director and is chair of its Remuneration Committee. He is also a member of the Audit Committee and the Nomination and Governance Committee.
Bristol Myers Squibb
Deepak Bhatt
Bristol Myers Squibb has appointed Deepak Bhatt to its board of directors and will serve as a member of the Science & Technology Committee of the Board of Directors. He is the executive director of interventional cardiovascular (CV) programmes at Brigham and Women’s Hospital, offering 20 years’ research experience in acute coronary syndromes.
Amgen
Michael Drake
Amgen has appointed Michael Drake to its board of directors. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee. He currently serves as president of the University of California. He previously served as president of The Ohio State University from 2014 to 2020.
Allogene Therapeutics
Stephen Mayo
Allogene Therapeutics has appointed Stephen Mayo to its board of directors. Mayo is the Bren Professor of Biology and Chemistry and Merkin Institute Professor at the California Institute of Technology, where he also served as vice provost for research from 2007 to 2010 and chairman of its Division of Biology and Biological Engineering from 2010 to 2020.
Hanover Health
James Mole
Hanover Health has appointed James Mole as a director. Mole joins from his role as deputy director of communications at NHS England. During his time at NHS England, he also served as head of media over the course of the COVID-19 pandemic, supporting regular Downing Street press conferences, managing journalist enquiries and offered senior counsel to NHS leaders.
Hanover Health
George Butterworth
Hanover Health has appointed George Butterworth as a senior account director in its policy, advocacy and public affairs team. He has fifteen years’ experience spanning government, parliament and healthcare charities – including Cancer Research UK and Diabetes UK. He developed a new smoking cessation strategy for England at the Department of Health and Social Care.
Evoke Mind+Matter
Mohinder Mann
Evoke Mind+Matter has appointed Mohinder Mann as its associate medical director. Mann brings over 20 years’ experience in delivering medical strategy for the pharmaceutical industry. He served as a senior marketing consultant at Ashfield Health, as head of marketing at Molnlycke Health Care, and from 1999 to 2008 he served as a global brand manager at AstraZeneca.
Evoke Mind+Matter
Nicole Moores
Evoke Mind+Matter has appointed Nicole Moores as its associate director of pharma and life sciences. Moores bring over two decades’ agency experience, having served in senior roles across medical communications. She served at 90Ten Healthcare as an account director and as an account manager at Cohn & Wolfe London, specialising in diabetes, patient behaviour and disease awareness.
Bedrock Healthcare Communications
Louise Adamson
Bedrock Healthcare Communications has appointed Louise Adamson as head of scientific services. Adamson will be responsible for driving science and strategy and will develop the scientific team. Her career covers nearly 15 years, having served at Chameleon Communications International as director of scientific services. She served at Health Interactions as a principle medical writer.
FCB Health Europe
Lucy Morgan
FCB Health Europe has appointed Lucy Morgan as its managing director. In her new role at the agency, she will report to Jonathan Kukathasan, president of IPG Health UK, with whom she worked alongside during her 18 years at the agency. Morgan served as managing partner of McCann Health London (also now part of IPG Health UK) where she began working in 2004. She also served as director of client services.
FCB Health Europe
Isabel Rojas
FCB Health Europe has appointed Isabel Rojas as its head of planning. Rojas will oversee the management of a team of planners in the UK, Germany and Spain. She originally joined FCB Health UK as engagement strategy director in 2021, having been at Havas Lynx Group where she served for over five years, most recently as head of strategy. Rojas previously served at KCOM as assistant propositions manager.
AXON
Sam Petyan
AXON has appointed Sam Petyan as its creative marketing lead. Petyan brings nearly 20 years’ experience in healthcare, commercial and marketing, having served as a Saatchi & Saatchi Wellness lead. A graduate of Biomedical Sciences, Petyan transferred from pharmaceutical sales into healthcare communications. He served at PAN Advertising as both an account manager and an account executive.
Onyx Health
Hope Johnston
Onyx Health has appointed Hope Johnston as digital content manager. Johnston joins the agency with experience in branding from Mediaworks, where she was a content strategist, working across client accounts regionally and nationally. Johnston worked for parent and baby brand, Tommee Tippee as a digital marketing manager and for Hebburn Sports Club as its marketing manager.
Onyx Health
Jordan Carr
Onyx Health has appointed Jordan Carr as its new social media executive. In October 2016, Carr began his career as a digital media apprentice at Newcastle University Students Union, before progressing to become a marketing assistant. He was responsible for overseeing the Student Union’s social media and creative content, which incorporated elements of video, digital and creative design.
Macomics
Lisa Seymour
Macomics has appointed Lisa Seymour as operations manager and health and safety officer. Seymour previously served at the Wellcome Trust Sanger Institute where she held multiple technical roles, including as an advanced laboratory technician in clinical microbiology, virology and parasitology. She is a member of the Institution of Occupational Safety and Health and the Royal Society of Biology.
Macomics
Thomas Crozier
Macomics has appointed Thomas Crozier as a senior scientist. Crozier joins from an academic role at the University of Cambridge and brings over ten years of research experience. He offers extensive knowledge into the use of unbiased genome and proteome-wide approaches to gene and protein function in a range of biological systems. Crozier received his PhD from the University of Dundee.